This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Drug Therapy, Other  • Neoplasms  • Drug Therapy  • Alert me on articles by topic

Sarah B. Newton, AB; Jessica S. Yoon, MD; Bernice M. Benoit, BS; Maria Wysocka, PhD; Alain H. Rook, MD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Cutaneous T-cell lymphoma (CTCL) is a malignant, lymphoproliferative disease of CD4⁺ skin-trafficking T cells. Sézary syndrome (SS), the erythrodermic variant, is typically characterized by circulating malignant T cells. Bexarotene, a retinoid X receptor–specific retinoid, has been available for SS treatment since 2000. A subset of patients with SS treated with bexarotene do not respond clinically, which may correlate with the findings of Budgin et al¹ that the malignant T cells from some patients with SS are resistant in vitro to the apoptotic effects of bexarotene.

All-trans retinoic acid (ATRA) is a retinoic acid receptor–specific member of the retinoic acid family approved by the US Food and Drug Administration for treatment of promyelocytic leukemia. Recently, ATRA has been used clinically to treat patients with CTCL.² The in vitro biologic actions of . . . [Full Text of this Article]

Methods


Results

Comment

AUTHOR INFORMATION